Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2022 | $16.00 | Outperform | Northland Capital |
| 7/13/2021 | $40.00 | Outperform | Wedbush |
| 7/13/2021 | $33.00 | Overweight | Morgan Stanley |
| 7/13/2021 | $23.00 | Buy | B of A Securities |
| 7/13/2021 | $30.00 | Overweight | JP Morgan |
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
3 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
15-12G - Cyteir Therapeutics, Inc. (0001662244) (Filer)
S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)
S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)
- Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022 - Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy to Phase 2 and initiated Phase 1 combination therapy study - Projected cash runway into 2024 to support planned R&D and clinical studies - Conference call and webcast scheduled for 4:30 p.m. ET on March 16, 2022 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the fourth quarter and full year
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir's website for 30 days. About Cyteir Therapeutics, Inc. Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthet
Northland Capital initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $16.00
Wedbush initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $40.00
Morgan Stanley initiated coverage of Cyteir Therapeutics with a rating of Overweight and set a new price target of $33.00
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising response and differentiated safety profile R&D Day outlined near-term strategic priorities and highlighted breadth of Bicycle® platform technology and ability to develop highly differentiated precision therapies for cancer and other diseases Stephen Sands appointed to Board of Directors Cash and cash equivalents of $526.4 million as of December 31, 2023, expected to provide financial runway into 2026 Bi
- CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile - Overall disease control rate was 91% in the capecitabine combination with a median progression-free survival of 170 days Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to
B of A Securities analyst Tazeen Ahmad downgrades Cyteir Therapeutics (NASDAQ:CYT) from Neutral to Underperform and announces $3 price target.
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13D/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs and Quality. "Krisztina has an impressive track record of leading regulatory functions and development teams at global pharmaceutical companies to successful worldwide product registrations in oncology, demonstrating extensive knowledge of global clinical trial approval processes and requirements, strategic thinking about development plans that maximize the likelihood of successful regulatory appl